Histrelin

Overview

Histrelin is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) agonist. It is delivered through a small implant placed under the skin of the upper arm that releases the drug steadily over approximately twelve months before being replaced. Two distinct formulations exist under the brand names Supprelin LA and Vantas, each developed for a different patient population.

Supprelin LA is approved for central precocious puberty, a condition in which children begin puberty abnormally early because of premature activation of the hypothalamic-pituitary-gonadal axis. Vantas, at a different dose, is approved for the palliative treatment of advanced prostate cancer. Both rely on the same underlying peptide and the same continuous-release principle.

The appeal of the implant format is consistency. Rather than requiring frequent injections, a single procedure provides sustained hormone suppression for about a year. This makes histrelin a notable example of how delivery technology, rather than the molecule alone, can shape a treatment's clinical role.

How it works

GnRH is normally released by the hypothalamus in pulses, and this rhythmic signaling tells the pituitary gland to produce luteinizing hormone and follicle-stimulating hormone, which in turn drive sex-hormone production. Histrelin binds the same GnRH receptors, but because the implant delivers the peptide continuously rather than in pulses, the signaling system behaves very differently.

Initially there is a brief surge in sex hormones, sometimes called a flare. With sustained exposure, however, the pituitary receptors become desensitized and downregulated. The result is a profound and reversible suppression of luteinizing hormone, follicle-stimulating hormone, and downstream sex steroids such as estrogen and testosterone.

In central precocious puberty, this suppression halts the premature progression of pubertal development. In prostate cancer, lowering testosterone to very low levels slows the growth of tumors that depend on androgens. The same mechanism therefore serves two clinically distinct goals: pausing puberty in children and achieving medical castration in adults.

Clinical evidence

Histrelin's approvals are supported by clinical studies demonstrating that the implant achieves and maintains hormonal suppression. In central precocious puberty, trials evaluated the implant's ability to lower luteinizing hormone to prepubertal levels and to halt or reverse signs of advancing puberty over the implant's lifespan.

For advanced prostate cancer, studies focused on whether the implant could reduce testosterone to castrate levels and keep it there, a recognized goal of androgen deprivation therapy. The evidence positioned histrelin alongside other GnRH agonists used in this setting rather than as a uniquely superior agent.

It is important to frame the evidence honestly. These studies primarily measured hormonal and biochemical endpoints, which are well-established surrogates for the intended effects. As with other GnRH agonists, histrelin is one of several interchangeable options, and the choice often comes down to delivery preference, cost, and clinician familiarity rather than demonstrated differences in long-term outcomes.

Dosing & side effects

This article does not provide dosing instructions. Histrelin is administered only by a healthcare professional as a subcutaneous implant inserted during a minor in-office procedure, and the implant is removed and potentially replaced after its release period. The specific product and configuration differ between the pediatric and oncology indications.

Reported side effects vary by population. In children, local implant-site reactions, bruising, and occasional implant breakage or difficulty with removal have been noted. In adults treated for prostate cancer, effects reflect low testosterone and can include hot flashes, fatigue, reduced libido, bone density loss with long-term use, and metabolic changes.

An initial hormonal flare can transiently worsen symptoms at the start of treatment, which is a recognized consideration in prostate cancer management. Because suppression is profound, medical monitoring is part of standard care. All decisions about starting, continuing, or stopping treatment belong with a qualified clinician.

Legal status

Histrelin is a prescription medication approved by the U.S. Food and Drug Administration. Supprelin LA is approved for central precocious puberty and Vantas for advanced prostate cancer, and both are available only through licensed healthcare providers who perform the implant procedure.

Because it is a regulated implantable drug-device product, histrelin is not something a patient can obtain or self-administer outside the medical system. Its placement and removal require clinical training, which reinforces its status as a professionally managed therapy.

Regulatory status can differ by country, and product availability changes over time as manufacturers update or discontinue specific formulations. Anyone with questions about access should consult a licensed prescriber rather than relying on general information.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Deeks ED. Histrelin: in advanced prostate cancer. Drugs. 2010. Peer-reviewed study
2. Barradell LB, McTavish D. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty. Drugs. 1993. Peer-reviewed study
3. Mak A, Hwang R, Nace G Jr, et al. Trends in Histrelin Implantation at a Pediatric Tertiary Care Center. J Surg Res. 2023. Peer-reviewed study
4. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. Drugs R D. 2005. Peer-reviewed study
5. Pine-Twaddell E, Newfield RS, Marinkovic M. Extended Use of Histrelin Implant in Pediatric Patients. Transgend Health. 2023. Peer-reviewed study
6. Swendiman RA, Vogiatzi MG, Alter CA, et al. Histrelin implantation in the pediatric population: A 10-year institutional experience. J Pediatr Surg. 2019. Peer-reviewed study